Linezolid

Linezolid exhibits its activity against several Gram-positive bacteria including penicillin-resistant, methicillin-resistant, and vancomycin- resistant. Linezolid can decrease the rate of translation reaction by inhibiting the formation of initiation complex thereby reducing the length of the newly formed peptidechain. Additionally, it may also play a role in reducing the virulence leading to reduced toxins produced by Gram-positive bacteria.

Linezolid has been used in checkerboard-type drug combination MIC (minimum inhibitory concentrations) assay to determine whether ivacaftor shows positive interaction with linezolid. It has been used for the determination of minimum biofilm inhibitory concentration and for the treatment of Mycobacterium abscessus-infected Drosophila melanogaster w1118 flies.Linezolid has been used as an antibiotic to study its effects on the development of malaria-associated acute respiratory distress syndrome (MAARDS) in rat lungs. It has been used as an antibiotic to study its effects in combination with baicalein on methicillin-resistant Staphylococcus aureus strains. It has been used as an antibiotic to study its effects on planktonic growth and formation of biofilms by Enterococcus faecalis.

Linezolid is an oxazolidinine antimicrobial. It inhibits bacterial mRNA translation and a weak, reversible, nonselective inhibitor of monoamine oxidase.

Linezolid is an oxazolidinone antimicrobial. It binds to a site on the bacterial 23S ribosomal RNA of the 50S subunit and prevents the formation of a functional 70S initiation complex, thus inhibiting bacterial mRNA translation. Linezolid is also a weak, reversible, nonselective inhibitor of monoamine oxidase.